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Abstract
Renal function in the first year after kidney transplantation (KT) can predict long-term renal
graft survival. This study investigated whether estimated glomerular filtration rate (eGFR)
variability during the first year after KT is a risk factor for poor renal allograft outcomes. This
retrospective cohort study included 3077 patients who underwent repeated eGFR measure-
ments for 1 year after KT at Severance Hospital Transplantation Center between 1979 and
2012. The eGFR variability during the first year after KT was the predictor. The patients
were divided into four quartile groups of eGFR variability according to the coefficient of varia-
tion for eGFR (eGFR-CV). We selected a cutoff of eGFR-CV for graft failure and performed
the sensitivity analyses. The graft outcome was worse in the highest quartile group of eGFR
variability than in the other groups among all patients (Q4: HR 1.631, 95% CI 1.278–2.081;
p < 0.0001) and among patients without AR (Q4: HR 1.425, 95% CI 1.024–1.982; p =
0.0358) after adjusting for eGFR at 1 year after KT and other covariates. Additionally, all-
cause mortality was higher in this highest quartile group than in the other groups among all
patients but not among patients without AR. Higher eGFR-CVs than the cutoff were signifi-
cantly associated with a high risk of graft failure among all patients (HR 1.670, 95% CI
1.395–2.000; p < 0.0001) and among patients without AR (HR 1.899, 95% CI 1.457–2.477;
p < 0.0001) after fully adjusting for covariates. For all-cause mortality, a higher eGFR-CV
was an independent risk factor among all patients but not among patients without AR after
adjusting for covariates. eGFR variability in the first year after KT is an independent risk fac-
tor for poor renal allograft outcomes.
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Introduction
Renal function within the first year after kidney transplantation (KT) has been shown to be an
important parameter that can influence long-term graft survival [1–5]. The estimated glomer-
ular filtration rate (eGFR) has been commonly used to evaluate kidney function, and changes
in the eGFR have been reported to be associated with the progression of kidney failure and
negative outcomes [6–8]. However, the assessment of a single eGFR may not provide sufficient
information on kidney function in different patients, who might have different levels of resil-
ience to kidney issues [9]. Some studies have attempted to use eGFRs obtained repeatedly for
modeling chronic kidney disease (CKD) progression with different statistical approaches,
including modeling of nonlinear trajectories [9–12]. Moreover, a recent study measured the
variability of kidney function by using repeated eGFR measurements and found that high vari-
ability was associated with an increased risk of death in stage 3–5 CKD patients [9, 13].
Although the graft attrition rate at 1 year after transplantation has improved, it has not
translated into a proportionate improvement in long-term renal graft survival [14, 15]. In
recent years, specific diseases, such as antibody-mediated rejection and de novo/recurrent glo-
merular diseases, have been identified as the primary causes of renal graft failure [15–18]. The
inability to prevent or treat these specific diseases is likely associated with the insufficient
improvement in long-term renal graft survival. One of the challenges for research in organ
transplantation is the identification of markers that can sufficiently diagnose these specific dis-
eases and that can be used as endpoints in clinical studies [15]. Additionally, many previous
studies have attempted to identify markers of renal graft injury that can be used to improve
long-term graft survival [15, 19–21].
The present study aimed to investigate whether eGFR variability during the first year after
KT is a risk factor for poor renal allograft outcomes in a large population of kidney transplant
recipients. It is important to realize the prognostic value of serial eGFR measurements during
the first year after KT, as these can be easily and noninvasively obtained in kidney transplant
recipients.
Subjects and Methods
Study population
This retrospective cohort study included adult patients who underwent KT at Severance Hos-
pital Transplantation Center between 1979 and 2012. Patients who had poor early graft func-
tion (eGFR of<30 mLmin-11.73 m-2 at 1 month after KT) and those who did not have repeat
eGFRs (every 3 months) during the first year after KT were excluded. A total of 3290 recipients
who underwent KT were considered for inclusion in this study. Of these patients, 213 met the
exclusion criteria and were not assessed. The immunosuppressive protocol was used as previ-
ously reported [5]. We also performed subgroup analysis for patients without an acute rejec-
tion (AR) episode during the first year after KT. This study was approved by the institutional
review board of Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, and
informed consent was waived owing to the retrospective nature of the study.
Clinical and pathological data
The clinical variables were donor and recipient age and sex, pre- and post-transplantation dia-
betes mellitus, hepatitis, dialysis duration before KT, human leukocyte antigen (HLA) mis-
matches, donor type (living related, living unrelated, and deceased), AR within 1 year of KT,
the primary immunosuppressant, kidney function during the first year after KT, graft loss, and
all-cause mortality. Kidney function was assessed with eGFRs that were calculated by using the
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PLOS ONE | DOI:10.1371/journal.pone.0168337 December 14, 2016 2 / 12
Competing Interests: The authors have declared
that no competing interests exist.
CKD-Epidemiology Collaboration equation based on serum creatinine levels [22]. AR was
defined according to the need for treatment, with or without biopsy confirmation. Graft failure
was defined as patient death, or conversion to maintenance dialysis.
eGFR variability
The mean eGFR and the eGFR variability were calculated as the mean and the coefficient of
variation of serial eGFR measurements for each patient. The coefficient of variation of eGFR
(eGFR-CV) was calculated as the ratio of the intra-individual standard deviation (SD) and
mean in order to correct for a large SD. eGFRs were obtained every 3 months during the
1-year period after KT. The patients were divided into four quartile groups of eGFR variability
according to the eGFR-CV and into four quartile groups of eGFR-mean.
Statistical analysis
Data are presented as mean ± SD for continuous variables or frequency (percentage) for cate-
gorical variables. Statistical differences in the clinical characteristics among the four quartile
groups according to eGFR-CV in the entire study group were determined using the analysis of
variance test for continuous variables and the chi-square test for categorical variables.
The Kaplan-Meier method was used to evaluate graft failure and all-cause mortality in the
four quartile groups by using the eGFR-mean and eGFR-CV. The estimated median time of
graft failure and death in each group was also evaluated. The cumulative event rates in the
groups were compared using the log-rank test. The method of Contal and O’Quigley was used
to select the optimal cutoff of the eGFR-CV for graft failure [23]. Univariate and multivariable
Cox regression analyses were performed to investigate the prediction of graft failure and all-
cause mortality in the four quartile groups by using the eGFR-CV and the eGFR-CV cutoff.
All analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC, USA) and R pack-
age version 2.14.2 (R Foundation for Statistical Computing, Vienna, Austria). A p-value <0.05
was considered statistically significant.
Results
A total of 3077 kidney transplant recipients were finally included in this study and were fol-
lowed up for a mean of 128.08 ± 83.54 months (Fig 1).
The baseline characteristics of the patients in the four quartile groups of eGFR variability
according to the eGFR-CV among all patients and among patients without AR during the first
year after KT are presented in Table 1. AR events during the first year were more common and
the eGFR at 1 year after KT was lower in the highest quartile group of eGFR variability than in
the other groups.
In Kaplan–Meier survival curve analysis, graft survival among all patients and among
patients without AR was lower in the lowest quartile group of the eGFR-mean than in the
other groups (Fig 2A and 2B). Additionally, in Kaplan–Meier survival curve analysis, graft sur-
vival among all patients and among patients without AR was lower in the highest quartile
group of eGFR variability than in the other groups (Fig 2C and 2D). The median graft failure
time was 187 months in the lowest quartile group of eGFR variability (Fig 2C), whereas the
median graft failure time was not obtained for the other quartile groups of eGFR variability
(Fig 2D). Although the median graft failure time was not obtained in all quartile groups of
eGFR variability among patients without AR, graft survival was found to be lower in the high-
est quartile group of eGFR variability than in the other groups.
In univariate Cox regression analysis for graft failure, the highest quartile group of eGFR
variability was significantly associated with a high risk of graft failure among all patients (Q4:
eGFR Variability Predicts Renal Allograft Outcomes
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hazard ratio [HR] 2.077, 95% confidence interval [CI] 1.708–2.527; p< 0.0001) and among
patients without AR (Q4: HR 1.537, 95% CI 1.117–2.114; p< 0.0001) (Table 2).
Multivariable Cox regression analysis for graft failure was performed after adjusting for
covariates based on the univariate Cox regression analysis (S1 Table). Interestingly, in this
analysis, the highest quartile group of eGFR variability was significantly associated with a high
risk of graft failure among all patients (Q4: HR 1.631, 95% CI 1.278–2.081; p< 0.0001) and
among patients without AR (Q4: HR 1.425, 95% CI 1.024–1.982; p = 0.0358) after adjusting for
eGFR at 1 year after KT and other covariates (Table 2).
We then investigated the effect of eGFR variability on all-cause mortality among all patients
and among patients without AR. In univariate Cox regression analysis for death, the highest
quartile group of eGFR variability was significantly associated with a high risk of death among
all patients (Q4: HR 2.077, 95% CI 1.708–2.527, p< 0.0001) and among patients without AR
(Q4: HR 1.537, 95% CI 1.117–2.114; p = 0.0083) (Table 3). Multivariable Cox regression analy-
sis for death was performed after adjusting for covariates based on the univariate Cox regres-
sion analysis (S2 Table). In this analysis, the highest quartile group of eGFR variability was
significantly associated with a high risk of death among all patients (Q4: HR 1.738, 95% CI
1.036–2.916; p = 0.0363). However, there was no significant association with a high risk of
death among patients without AR after adjusting for covariates (Table 3).
Sensitivity analyses
We used the method of Contal and O’Quigley to select a cutoff of eGFR-CV for graft failure
[24], and we generated Kaplan–Meier survival curves with this cutoff. The cutoffs of 0.1832
among all patients and 0.1859 among patients without AR were selected using the abovemen-
tioned method. Kaplan–Meier survival curves with the cutoffs of eGFR-CV revealed that graft
survival was significantly lower in the group with higher eGFR-CV than the cutoff than in the
group with lower eGFR-CVs than the cutoff among all patients (Fig 3A) and among patients
without AR (Fig 3B).
In univariate Cox regression analysis for graft failure according to the cutoff of eGFR-CV, a
higher eGFR-CVs than the cutoff was associated with a high risk of graft failure among all
Fig 1. Algorithm used to define the study cohort.
doi:10.1371/journal.pone.0168337.g001
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Fig 2. Kaplan–Meier curves for the median time of graft survival according to eGFR variability. Upper
panel: Kaplan–Meier survival curves for graft failure by quartiles of the means of serially measured eGFR
values in all patients (A) and in patients without AR (B) (black: quartile 1, black dotted: quartile 2, gray: quartile
3, gray dotted: quartile 4). Lower panel: Kaplan–Meier survival curves for graft failure by quartiles of the CV of
serially measured eGFR values in all patients (C) and in patients without AR (D) (black: quartile 4, black
dotted: quartile 3, gray: quartile 2, gray dotted: quartile 1). Black and gray lines indicate the quartile of eGFR-
means or eGFR-CV values. eGFR: estimated glomerular filtration rate; AR: acute rejection; CV: coefficient of
variation of eGFR.
doi:10.1371/journal.pone.0168337.g002
Table 2. Cox regression model for graft failure by quartiles of eGFR variability.
All patients Patients without AR
Variables HR (95% CI) p-Value Variables HR (95% CI) p-Value
Unadjusted
Q1 (0.09) 1(Ref) Q1 (0.08) 1(Ref)
Q2 (0.10–0.12) 1.015(0.806–1.277) 0.9021 Q2 (0.09–0.12) 1.037(0.743–1.447) 0.8329
Q3 (0.13–0.18) 1.050(0.854–1.292) 0.6411 Q3 (0.13–0.16) 1.025(0.727–1.444) 0.8888
Q4 (>0.18) 2.077(1.708–2.527) <0.0001 Q4 (>0.16) 1.537(1.117–2.114) 0.0083
Adjusted a Adjusted b
Q1 (0.09) 1(Ref) Q1 (0.08) 1(Ref)
Q2 (0.10–0.12) 0.977(0.745–1.281) 0.8659 Q2 (0.09–0.12) 1.008(0.719–1.413) 0.9630
Q3 (0.13–0.18) 1.084(0.850–1.383) 0.5148 Q3 (0.13–0.16) 1.063(0.748–1.509) 0.7344
Q4 (>0.18) 1.631(1.278–2.081) <0.0001 Q4 (>0.16) 1.425(1.024–1.982) 0.0358
a: Adjusted by sex, donor age, donor type, HLA mismatches, DM, hepatitis, AR, eGFR at 1 year post-KT,
and main immunosuppressant
b: adjusted by sex, recipient and donor age, HLA mismatches, DM, hepatitis, eGFR at 1 year post-KT, and
main immunosuppressant
HR: hazard ratio; CI: confidence interval; Ref: reference; AR: acute rejection; eGFR: estimated glomerular
filtration rate; eGFR-CV: coefficient of variation of the estimated glomerular filtration rate; HLA: human
leukocyte antigen; DM, diabetes mellitus; KT: kidney transplantation.
doi:10.1371/journal.pone.0168337.t002
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Fig 3. Kaplan–Meier survival curves for graft failure by using the cutoff of the eGFR-CV of serially
measured eGFR values in all patients (A) and in patients without AR (B). Black and gray lines indicate
the cutoff of eGFR-CV (black: higher-CV, gray: lower-CV). eGFR: estimated glomerular filtration rate; AR:
acute rejection; CV: coefficient of variation of eGFR; higher-CV: higher values than the cutoff of eGFR-CV;
lower-CV: lower values than the cutoff of eGFR-CV.
doi:10.1371/journal.pone.0168337.g003
Table 3. Cox regression model for death by quartiles of eGFR variability.
All patients Patients without AR
Variables HR (95% CI) p-Value Variables HR (95% CI) p-Value
Unadjusted Unadjusted
Q1 (0.09) 1(Ref) Q1 (0.08) 1(Ref)
Q2 (0.10–0.12) 1.015(0.806–1.277) 0.9021 Q2 (0.09–0.12) 1.037(0.743–1.447) 0.8329
Q3 (0.13–0.18) 1.050(0.854–1.292) 0.6411 Q3 (0.13–0.16) 1.025(0.727–1.444) 0.8888
Q4 (>0.18) 2.077(1.708–2.527) <0.0001 Q4 (>0.16) 1.537(1.117–2.114) 0.0083
Adjusted a Adjusted b
Q1 (0.09) 1(Ref) Q1 (0.08) 1(Ref)
Q2 (0.10–0.12) 1.042(0.579–1.876) 0.8905 Q2 (0.09–0.12) 0.719(0.320–1.616) 0.4249
Q3 (0.13–0.18) 1.383(0.829–2.307) 0.2143 Q3 (0.13–0.16) 0.731(0.316–1.693) 0.4645
Q4 (>0.18) 1.738(1.036–2.916) 0.0363 Q4 (>0.16) 1.197(0.561–2.553) 0.6418
a: Adjusted by sex, age, donor type, DM, hepatitis, AR, and main immunosuppressant
b: adjusted by age, donor type, DM, hepatitis, and eGFR at 1 year post-KT
HR: hazard ratio; CI: confidence interval; Ref: reference; AR: acute rejection; eGFR: estimated glomerular
filtration rate; DM, diabetes mellitus; KT: kidney transplantation.
doi:10.1371/journal.pone.0168337.t003
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patients and among patients without AR. Moreover, in multivariable Cox regression analysis,
a higher eGFR-CVs than the cutoff was significantly associated with a high risk of graft failure
among all patients (HR 1.670, 95% CI 1.395–2.000; p< 0.0001) and among patients without
AR (HR 1.899, 95% CI 1.457–2.477; p< 0.0001) after fully adjusting for covariates, including
eGFR at 1 year after KT (Table 4).
We then performed univariate and multivariable Cox regression analyses for death accord-
ing to the cutoff of eGFR-CV. In the univariate Cox regression analysis, a higher eGFR-CVs
than the cutoff was significantly associated with a high risk of death among all patients (HR
1.969, 95% CI 1.555–2.492; p< 0.0001); however, there was no significant association with a
high risk of death among patients without AR (HR 1.822, 95% CI 0.998–3.325; p = 0.0507). In
multivariable Cox regression analysis, a higher eGFR-CVs than the cutoff was significantly
associated with a high risk of death among all patients after adjusting for covariates (HR 1.579,
95% CI 1.104–2.257; p = 0.0122); however, there was no significant association with a high risk
of death among patients without AR after adjusting for covariates (Table 4).
Discussion
We found that high eGFR variability in the first year after KT was associated with a high risk
of graft failure. This risk was independent of well-known risk factors for kidney graft failure,
such as donor type, HLA mismatches, and eGFR at 1 year after transplantation. We also noted
a significant association between eGFR variability and all-cause mortality in all patients who
underwent KT; however, this association was not significant in patients without AR episodes
during the first year after KT.
To our knowledge, this is the first study to investigate the effects of eGFR variability on
long-term graft survival in kidney transplant recipients. To date, single renal function parame-
ters and changes in renal function, represented as delta creatinine between different time
points during the first year after KT, have been reported as predictors for graft survival. In a
previous large-scale retrospective survey, renal function assessed by using the serum creatinine
levels at 1 year after transplantation was significantly associated with graft survival [1]. Inter-
estingly, when renal function within the first year and clinical AR were included in the regres-
sion model for long-term graft survival, only the 1-year creatinine level and changes in
Table 4. Cox regression model for graft failure and death by using the cutoff of eGFR variability.
All patients Patients without AR
Variables HR (95% CI) p-Value Variables HR (95% CI) p-Value
Graft failure
Unadjusted 2.106 (1.824–2.431) <0.0001 Unadjusted 1.996 (1.563–2.550) <0.0001
Adjusteda 1.670 (1.395–2.000) < .0001 Adjusted b 1.899 (1.457–2.477) <0.0001
Death
Unadjusted 1.969 (1.555–2.492) <0.0001 Unadjusted 1.822 (0.998–3.325) 0.0507
Adjusted c 1.579 (1.104–2.257) 0.0122 Adjusted d 1.522 (0.782–2.961) 0.2163
a: Adjusted by sex, donor age, donor type, HLA mismatches, DM, hepatitis, AR, eGFR at 1 year post-KT,
and main immunosuppressant
b: adjusted by sex, recipient and donor age, HLA mismatches, DM, hepatitis, eGFR at 1 year post-KT, and
main immunosuppressant
c: adjusted by sex, age, donor type, DM, hepatitis, AR, and main immunosuppressant
d: adjusted by age, donor type, DM, hepatitis, and eGFR at 1 year post-KT
eGFR: estimated glomerular filtration rate; AR: acute rejection; HR: hazard ratio; CI: confidence interval.
doi:10.1371/journal.pone.0168337.t004
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creatinine values showed significance. A previous multicenter study has shown that serum cre-
atinine measurements at 6 and 12 months can predict the 3-year graft survival [2]. In that
study, a Cox regression analysis showed that serum creatinine levels at both 6 and 12 months
after transplantation and the change in the serum creatinine level between these time points
were important predictors of graft loss at 3 years after transplantation.
Recently, eGFR variability has been reported to indicate reduced kidney resilience to sti-
muli, and it might be a risk factor for kidney failure [9]. Some studies have attempted to use
repeated measurements of the eGFR to model CKD progression by using different statistical
approaches, including modeling of nonlinear trajectories [9–12]. In the present study, we also
used repeated measurements of the eGFR in the first year after transplantation and calculated
the eGFR variability. Multivariable Cox regression analysis revealed that a high eGFR variabil-
ity was associated with a high risk of graft failure after fully adjusting for covariates that were
well-known risk factors for graft failure, such as sex, age, donor type, HLA mismatches, diabe-
tes mellitus, hepatitis, AR during the first year after KT, the primary immunosuppressant, and
a single eGFR at 1 year after KT, among all patients and among patients without AR episodes
in the first year.
Although new surrogate markers for late graft failure have been reported, renal function
remains the best measure for predicting outcomes [15, 25]. However, it has been shown that
measurement of kidney function at a fixed time after transplantation was not always predictive
of the decline in function over time [25, 26]. Changes in the eGFR between 3 and 12 months
after transplantation were shown to have a U-shaped relationship with graft failure, whereby
both decreasing and increasing eGFRs were associated with poor outcomes [3]. This U-shaped
relationship indicates that the eGFR variability itself may increase the risk of graft failure
regardless of the slope of the eGFR trajectory in kidney transplant recipients.
Previous studies used eGFR variability in CKD patients as SDs, concurrent means, and
slopes of eGFR progression [9, 27]. We measured eGFR variability as eGFR-CV, calculated by
using the ratio of the intraindividual SD and the mean of repeated eGFR measurements during
the first year after KT. As a normalized measure of variability, eGFR-CV was calculated as the
ratio of the intrapersonal SD and mean to correct for large SDs because of high absolute
eGFRs [28]. In the present study, we selected an eGFR-CV cutoff for graft failure by using the
method of Contal and O’Quigley. This calculation can easily be used by clinicians for assessing
renal allograft management. After KT, a clinician can assess a patient’s eGFR-CV in the first
year, and the clinician should consider investigating acute kidney injury or other issues in
patients with a high eGFR-CV, which indicates increased variability of renal function [9].
Several factors might explain the observed relationship between eGFR variability and renal
graft failure. The variability of renal function may be related to loss of nephron mass, changes
in renal plasma flow, or endothelial dysfunction. These factors have been shown to possibly be
associated with death in kidney transplant recipients, and these factors can occur in CKD
patients [27]. Furthermore, these factors can result in chronic allograft nephropathy (CAN),
which is a major cause of late graft loss [29, 30]. Chronic rejection as a cause of graft loss was
more common in kidney transplant recipients with a high eGFR variability in this study (data
not shown), indicating that eGFR variability might be associated with an immune reaction,
such as subclinical rejection, which could be related with CAN [31]. A previous report found
that up to 27% of patients presented with subclinical rejection at 1 year after transplantation,
without the clinician being aware of the condition. Additionally, the finding of normal and sta-
ble allograft function, represented by serum creatinine, has been observed despite biopsies
showing lymphocytic infiltrates [32]. Accordingly, our results showing that eGFR variability is
associated with graft loss independently with a single assessment of eGFR after KT are clini-
cally important. This suggests that dynamic eGFR changes may provide appropriate predictive
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information for subclinical rejection and late graft loss together with traditional risk factors
and renal function at a fixed time point.
A recent retrospective study reported that eGFR variability could predict death among
patients with stage 3 CKD independent of previously well-known risk factors, such as diabetes,
proteinuria, serum albumin, baseline eGFR, and eGFR slope [27]. Similarly, the present study
revealed that high eGFR variability was associated with a significantly high risk of all-cause
mortality among all kidney transplant recipients. However, eGFR variability and eGFR at 1
year after KT did not show any significant association with the risk of death among patients
without AR. It is believed that other traditional risk factors for death, such as age, hypertension
or diabetes status, and duration of pre-KT dialysis, are important in kidney transplant recipi-
ents without AR episodes in the first year after KT; however, the mechanisms are unclear [14].
The present study has several limitations. First, this was a retrospective study. Second, we
did not evaluate the level of the calcineurin inhibitor, which can affect the kidney graft out-
come. Third, the findings are limited by the inherent issues of serum creatinine, which is
dependent on muscle mass, and generation and tubular secretion of creatinine [6, 16]. A previ-
ous study showed that low serum creatinine levels could result from muscle wasting caused by
comorbid conditions in kidney transplant recipients [3]. Fourth, eGFR variability was assessed
in patients who underwent KT at a single center. Therefore, to utilize this factor in other KT
populations, the relative predictive strengths of various variability derivations should be tested.
Finally, in this study, we could not investigate time-dependent covariates for outcomes in the
transplant recipients. Kasiske et al. found that measures of change in chronic renal function,
such as the duration of the first decline in inverse creatinine, declines in estimated creatinine
clearance, and declines in the measured slope of 1/creatinine over time after KT, were better
outcome predictors than baseline function and slope of inverse serum creatinine [26].
In conclusion, we found that eGFR variability in the first year after KT is an independent
risk factor for poor renal allograft outcomes. Our results suggest that eGFR variability calcu-
lated by using serum creatinine may help predict long-term graft survival in kidney transplant
recipients. Those who have higher eGFR variability should be monitoring carefully for pre-
venting worse graft outcome.
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